GLP-1oral semaglutideglp-1 receptor agonisttype 2 diabetesadherence

Review finds higher adherence with oral than injectable GLP-1 agonists

Across 13 studies covering 1,348 patients with type 2 diabetes, persistence was 62.1% for oral formulations versus 47.8% for injectables.

By Maren Holt · Senior Reporter, GLP-1

Oct 11 20:00 ETSource: Diabetes, metabolic syndrome and obesity : targets and therapy

The wire

01A systematic review with descriptive pooled synthesis reported adherence of 70.8% for oral GLP-1 receptor agonists versus 62.4% for injectables, and persistence of 62.1% versus 47.8%, both statistically significant by chi-square.
02Formulation choice may shape long-term continuation, a practical consideration for prescribers and pharmacies managing type 2 diabetes patients; injectables showed more adverse events, particularly injection-site reactions.
03The synthesis was descriptive rather than a formal meta-analysis, drew on mixed real-world and trial sources, and the authors call for study-level meta-analytic work.

From the source

Adherence and Persistence to Injectable versus Oral GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Comparative Systematic Review and Analysis
Diabetes, metabolic syndrome and obesity : targets and therapy · 2026 · Ashour AM et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42893177/